BERG, DoD Using AI Platform to Ready Diagnostic Test for Prostate Cancer

CPDR is a comprehensive research program to study prostate cancer and prostate disease.

A nice entry 6


A nice entry 2

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem.

Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Nullam dictum felis eu pede mollis pretium. Integer tincidunt. Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim.

Read more

Big Data: Is It Crunch Time for Pharma?

With big data and advanced analytics progressing from fad to frontier status, Pharm Exec examines the readiness of the biopharma industry to take advantage of this promise. Can new digital health tools be harnessed to help advance new treatment approaches and aid decision-making?

Read More

BD Taps BERG’s AI Platform to Reduce Medication Non-Adherence

BD (Becton, Dickinson and Company) a leader in medical technology, will use BERG‘s artificial intelligence platform to improve patient health by minimizing challenges associated with medication adherence for patients. The partnership will leverage BD’s healthcare IT expertise and BERG’s AI platform to develop a medication adherence algorithm that will help healthcare workers identify certain patient populations that are at the highest risk for nonadherence post-discharge.

Read More

AI in Medicine Journal: Berg Analytics Research Paper

Non-obvious correlations to disease management unraveled by Bayesian artificial intelligence analyses of CMS data

• Data-driven Bayesian networks based analysis has been performed on health care data.
• Summarized, healthcare provider level data was used for this analysis.
• Novel hypothesis linking diagnosis codes was proposed based on findings from Bayesian networks approach.
• Potential mechanisms were explored to explain novel hypothesis.
• This paper demonstrates the ability of artificial intelligence methods to advance medical research.

Read More

CEO Niven Narain Discusses AI, AstraZeneca Partnership on BBC’s “Talking Business”

BBC “Talking Business” Host Aaron Heslehurst interviews BERG CEO Niven Narain. In addition to discussing how artificial intelligence can improve the drug-development process, Narain talks about BERG’s new collaboration with AstraZeneca.  

BERG Forms Research Collaboration with AstraZeneca

BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced a research collaboration with
AstraZeneca to identify and evaluate novel targets and therapeutics to treat neurological disorders such as Parkinson’s disease.

Wall Street Journal: How AI Is Transforming Drug Creation

The Wall Street Journal’s Daniela Hernandez talks to BERG about efforts to advance drug discovery through the use of AI. BERG’s Project Survival is featured as a key example of how we are working to improve the lives of patients through the use of AI technology.

You can read the full article here: